Evidence item

The phase 1 report describes 40 healthy adult participants and no serious adverse events during the study. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 18303

Source: A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial · locator {} · excerpt hash sha256:db486f54db6feff2158b416060f25de9d8f8659349f1026f10a92df01f8cd3ab

Forty healthy adults ... were enrolled into the 10-, 25-, 50- or 100-μg dose groups with ten participants per group. ... Overall, the vaccine was well tolerated. No serious AEs occurred during the study.